U.S. Pharmaceutical Market Size, Share, and Trends 2025 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. U.S. Pharmaceutical Market, By Type

7.1. U.S. Pharmaceutical Market Revenue and Volume, by Type

7.1.1. Prescription

7.1.1.1. Market Revenue and Volume Forecast

7.1.2. OTC

7.1.2.1. Market Revenue and Volume Forecast

Chapter 8. U.S. Pharmaceutical Market, By Molecule Type

8.1. U.S. Pharmaceutical Market Revenue and Volume, by Molecule Type

8.1.1. Biologics & Biosimilars (Large Molecules)

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Conventional Drugs (Small Molecules)

8.1.2.1. Market Revenue and Volume Forecast

Chapter 9. U.S. Pharmaceutical Market, By Product

9.1. U.S. Pharmaceutical Market Revenue and Volume, by Product

9.1.1. Branded

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Generics

9.1.2.1. Market Revenue and Volume Forecast

Chapter 10. U.S. Pharmaceutical Market, By Disease

10.1. U.S. Pharmaceutical Market Revenue and Volume, by Disease

10.1.1. Cardiovascular diseases

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Cancer

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Diabetes

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Infectious diseases

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Neurological disorders

10.1.5.1. Market Revenue and Volume Forecast

10.1.5. Respiratory diseases

10.1.6.1. Market Revenue and Volume Forecast

10.1.6. Autoimmune diseases

10.1.7.1. Market Revenue and Volume Forecast

10.1.7. Mental health disorders

10.1.8.1. Market Revenue and Volume Forecast

10.1.8. Gastrointestinal disorders

10.1.9.1. Market Revenue and Volume Forecast

10.1.9. Women’s health diseases

10.1.10. Market Revenue and Volume Forecast

10.1.10.1 Genetic and rare genetic diseases

10.1.11. Market Revenue and Volume Forecast

10.1.11.1 Dermatological conditions

10.1.12. Market Revenue and Volume Forecast

10.1.12.1. Obesity

10.1.13. Market Revenue and Volume Forecast

10.1.13.1 Renal diseases

10.1.14. Market Revenue and Volume Forecast

10.1.14.1 Liver conditions

10.1.15. Market Revenue and Volume Forecast

10.1.15.1. Hematological disorders

10.1.16. Market Revenue and Volume Forecast

10.1.16.1. Eye conditions

10.1.17. Market Revenue and Volume Forecast

10.1.17.1. Infertility conditions

10.1.18. Market Revenue and Volume Forecast

10.1.18.1. Endocrine disorders

10.1.19. Market Revenue and Volume Forecast

10.1.19.1. Allergies

10.1.20. Market Revenue and Volume Forecast

10.1.20.1. Others

10.1.5.1. Market Revenue and Volume Forecast

Chapter 11. U.S. Pharmaceutical Market, By Route of Administration

11.1. U.S. Pharmaceutical Market Revenue and Volume, by Route of Administration

11.1.1. Oral

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Topical

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Parenteral

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Inhalations

11.1.4.1. Market Revenue and Volume Forecast

11.1.5. Others

11.1.5.1. Market Revenue and Volume Forecast

Chapter 12. U.S. Pharmaceutical Market, By Age Group

12.1. U.S. Pharmaceutical Market Revenue and Volume, by Age Group

12.1.1. Children & Adolescents

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Adults

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Geriatric

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Discrete

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. U.S. Pharmaceutical Market, By Distribution Channel

13.1. U.S. Pharmaceutical Market Revenue and Volume, by Distribution Channel

13.1.1. Hospital Pharmacy

13.1.1.1. Market Revenue and Volume Forecast

13.1.2. Retail Pharmacy

13.1.2.1. Market Revenue and Volume Forecast

13.1.3. Others

13.1.3.1. Market Revenue and Volume Forecast

Chapter 14. U.S. Pharmaceutical Market, Regional Estimates and Trend Forecast

14.1.8. U.S.

14.1.8.1. Market Revenue and Volume Forecast, by Type

14.1.8.2. Market Revenue and Volume Forecast, by Molecule Type

14.1.8.3. Market Revenue and Volume Forecast, by Product

14.1.8.4. Market Revenue and Volume Forecast, by Disease

14.1.8.5. Market Revenue and Volume Forecast, by Route of Administration

14.1.8.6. Market Revenue and Volume Forecast, by Distribution Channel

14.1.8.7. Market Revenue and Volume Forecast, by Age Group

Chapter 15. Company Profiles

15.1. Merck & Co., Inc.

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. F. Hoffmann-La Roche Ltd

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Johnson & Johnson Services, Inc.

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Novartis AG

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. AbbVie Inc.

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. GlaxoSmithKline plc.

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. AstraZeneca

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Pfizer Inc.

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Bristol-Myers Squibb Company

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Sanofi

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms